Stefan Laufer

87PUBLICATIONS
165CO-AUTHORS
Molecular targetsCheminformatics and quantitative structure-activity relationshipsProteins and peptidesBiomolecular modelling and designCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (87)

|Jul 13, 2026
Riding toward Selectivity: Optimization of Covalent 7-Azaindole-Based BMX Kinase Inhibitors.

|Jun 10, 2026
Computational Discovery and Optimization of a Potent, Selective, and Drug-Like Scaffold for p38α Inhibition.

|May 06, 2026
Darizmetinib (HRX215): A Promising 1st-in-Class Liver Regenerating Drug in Phase 1b/2a Clinical Development, Targeting the Stress Signaling Protein Kinase MKK4.

|Sep 11, 2025
Azapeptide-Based SARS-CoV-2 Main Protease Inhibitors: Design, Synthesis, Enzyme Inhibition, Structural Determination, and Antiviral Activity.

Philipp Flury, Jyoti Vishwakarma, Katharina Sylvester

|Aug 04, 2025
A twist in the tale: shifting from covalent targeting of a tyrosine in JAK3 to a lysine in MK2.

Laura Hillebrand, Guiqun Wang, Alexander Rasch

|Jul 11, 2025
Discovery of the First Highly Selective 1,4-dihydropyrido[3,4-b]pyrazin-3(2H)-one MKK4 Inhibitor.

Leon Katzengruber, Pascal Sander, Stefan Zwirner

Pageof 15

Frequent Collaborators

16 joint publications

Stefan Knapp

13 joint publications

Matthias Gehringer

13 joint publications

Thanigaimalai Pillaiyar

12 joint publications

Antti Poso